Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer.

Deniz Tataroğlu ÖzyükselerMustafa BasakSeval AyAygül KoseogluSerdar ArıcıAbdilkerim OymanHeves SürmeliMerve TuranNedim TuranHatice OdabaşMahmut E Yıldırım

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Trastuzumab emtansine prolongs progression-free survival and overall survival with a manageable safety profile. Thrombocytopenia, Eastern Cooperative Oncology Group-Performance Status, and cancer antigen 15-3 are correlated with progression-free survival and/or overall survival.

Keyphrases

free survival
positive breast cancer
prognostic factors
metastatic breast cancer
epidermal growth factor receptor
papillary thyroid
palliative care
south africa
squamous cell
squamous cell carcinoma
tyrosine kinase
childhood cancer